Table 1.

(A and B) RNA protection analysis by RNA protection assay (RPA) of spinal cord samples from lenalidomide-treated and control G93A SOD1 mice showing lenalidomide modulates cytokines in the spinal cord of G93A SOD1 mice.

Cytokines	Non-Tg controls (%) n =6	G93A Control (%) n =6	G93A + lenalidomide (%) n=6	Percentage of change in G93A control vs. G93A +Lenalidomide
(A) List of reduced cytokines
IL-1α	100.00	409	351	−14% P< 0.04
IL-1β	100.00	379	330	−13% n.s.
IL-18	100.00	169	163	−3% n.s.
MIF	100.00	119	113	−5% n.s.
TNF-α	100.00	358	261	−25% P< 0.0001
IFNβ	100.00	130	114	−12% n.s.
TGFβ1	100.00	310	273	−12% P< 0.03
TGFβ2	100.00	163	149	−8% n.s.
FADD	100.00	142	139	−2% n.s.
FAP	100.00	236	131	−44% P< 0.0001
FAF	100.00	264	105	−60% P< 0.0001
(B) List of increased cytokines
IL-1RA	100.00	453	632	39% P< 0.0001
TGFβ3	100.00	122	140	15% n.s.
FAS	100.00	236	275	16% n.s.
TRAIL	100.00	135	161	19% n.s.
TNFRp55	100.00	264	295	12% n.s.
TRADD	100.00	100	108	8% n.s.
RIP	100.00	148	165	11% n.s.

Numbers are expressed as percent of change in treated vs. untreated G93A mice. Not significant (n.s.).